[HTML][HTML] Coagulome and the tumor microenvironment: an actionable interplay
A Galmiche, J Rak, LT Roumenina, Z Saidak - Trends in Cancer, 2022 - cell.com
Human tumors often trigger a hypercoagulable state that promotes hemostatic
complications, including venous thromboembolism. The recent application of systems …
complications, including venous thromboembolism. The recent application of systems …
[HTML][HTML] The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review
J Zhou, Q Yi, L Tang - Journal of Experimental & Clinical Cancer Research, 2019 - Springer
FAK is a tyrosine kinase overexpressed in cancer cells and plays an important role in the
progression of tumors to a malignant phenotype. Except for its typical role as a cytoplasmic …
progression of tumors to a malignant phenotype. Except for its typical role as a cytoplasmic …
Multispectral fluorine-19 MRI enables longitudinal and noninvasive monitoring of tumor-associated macrophages
D Croci, R Santalla Méndez, S Temme… - Science Translational …, 2022 - science.org
High-grade gliomas, the most common and aggressive primary brain tumors, are
characterized by a complex tumor microenvironment (TME). Among the immune cells …
characterized by a complex tumor microenvironment (TME). Among the immune cells …
[HTML][HTML] SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia
LH Geraldo, Y Xu, L Jacob… - The Journal of …, 2021 - Am Soc Clin Investig
SLIT2 is a secreted polypeptide that guides migration of cells expressing Roundabout 1 and
2 (ROBO1 and ROBO2) receptors. Herein, we investigated SLIT2/ROBO signaling effects in …
2 (ROBO1 and ROBO2) receptors. Herein, we investigated SLIT2/ROBO signaling effects in …
TGF-β promotes microtube formation in glioblastoma through thrombospondin 1
JV Joseph, CR Magaut, S Storevik, LH Geraldo… - Neuro …, 2022 - academic.oup.com
Abstract Background Microtubes (MTs), cytoplasmic extensions of glioma cells, are
important cell communication structures promoting invasion and treatment resistance …
important cell communication structures promoting invasion and treatment resistance …
[HTML][HTML] Tumor vessels fuel the fire in glioblastoma
S Rosińska, J Gavard - International Journal of Molecular Sciences, 2021 - mdpi.com
Glioblastoma, a subset of aggressive brain tumors, deploy several means to increase blood
vessel supply dedicated to the tumor mass. This includes typical program borrowed from …
vessel supply dedicated to the tumor mass. This includes typical program borrowed from …
Identification of diverse tumor endothelial cell populations in malignant glioma
JC Carlson, M Cantu Gutierrez, B Lozzi… - Neuro …, 2021 - academic.oup.com
Background Glioblastoma is the most common and aggressive type of primary brain tumor,
as most patients succumb to the disease less than two years after diagnosis. Critically …
as most patients succumb to the disease less than two years after diagnosis. Critically …
Glioblastoma therapy in the age of molecular medicine
LHM Geraldo, C Garcia, ACC da Fonseca, LGF Dubois… - Trends in cancer, 2019 - cell.com
Glioblastoma (GBM) is the most common and fatal primary malignant brain tumor. Despite
advances in the understanding of the biology of gliomas, little has changed in the treatment …
advances in the understanding of the biology of gliomas, little has changed in the treatment …
[HTML][HTML] Glioma stem cell-derived exosomal miR-944 reduces glioma growth and angiogenesis by inhibiting AKT/ERK signaling
J Jiang, J Lu, X Wang, B Sun, X Liu, Y Ding… - Aging (Albany …, 2021 - ncbi.nlm.nih.gov
In this study, we investigated the regulatory role of exosomal microRNA-944 (miR-944)
derived from glioma stem cells (GSCs) in glioma progression and angiogenesis …
derived from glioma stem cells (GSCs) in glioma progression and angiogenesis …
Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma
L Finotto, B Cole, W Giese, E Baumann… - EMBO Molecular …, 2023 - embopress.org
Glioblastoma (GBM) remains the most malignant primary brain tumor, with a median survival
rarely exceeding 2 years. Tumor heterogeneity and an immunosuppressive …
rarely exceeding 2 years. Tumor heterogeneity and an immunosuppressive …